Compare STEM & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | RLYB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 92.3M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | RLYB |
|---|---|---|
| Price | $7.36 | $16.00 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 136.9K | 57.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $858,000.00 |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $14.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.08 | ★ 43.00 |
| 52 Week Low | $6.04 | $0.32 |
| 52 Week High | $32.23 | $17.57 |
| Indicator | STEM | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 64.94 |
| Support Level | $7.20 | $0.57 |
| Resistance Level | $10.96 | $17.57 |
| Average True Range (ATR) | 0.55 | 0.47 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 13.14 | 67.03 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.